All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
How does MRD impact outcome of stem cell transplantation in AML, now and in the future?
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, the AML Hub will hold a Satellite Symposium on the impact of measurable residual disease (MRD) on stem cell transplantation (SCT) outcome in patients with acute myeloid leukemia.
Save to your areas of interest